Evidence map›Paper›PMID 37194386›Full record

ArticleIET nanobiotechnology2023

Inhibition of pulmonary artery smooth muscle cells via the delivery of curcuminoid WZ35 by Cu-based metal organic frameworks.

Zhidan Hua, Mingming Han, Lanlan Song, Yongle Yan, Honglang Chen, Jilong Wang, Chao Li, Yanfan Chen, Hanhan Yan, Mayun Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IET nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Zhidan HuaDepartment of Pulmonary and Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, China.
Mingming HanDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Lanlan SongDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yongle YanDepartment of Pulmonary and Critical Care Medicine, The Longgang People's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Honglang ChenDepartment of Pulmonary and Critical Care Medicine, The Longgang People's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Jilong WangZhejiang Engineering Research Center for Tissue Repair Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang, China.
Chao LiDepartment of Pulmonary and Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, China.
Yanfan ChenDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Hanhan YanDepartment of Pulmonary and Critical Care Medicine, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Mayun ChenDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.ORCID https://orcid.org/0000-0001-5403-4204
Wenzhou Medical University · CNWenzhou University · CN

Funding

Research Business Fund Project of Wenzhou Medical University KYYW202126Wenzhou Municipal Science and Technology Bureau project Y2020250Zhejiang Provincial Health Commission 2019RC047Zhejiang Provincial Natural Science Foundation of China LQ19H010003Zhejiang Provincial Natural Science Foundation of China LY19H290010
6 · The paper itself

Abstract

Hypoxic pulmonary hypertension (HPH) is a life-threatening disease that occurs due to a lack of oxygen in the lungs, leading to an increase in pulmonary vascular resistance, right ventricular failure, and ultimately death. HPH is a multifactorial disorder that involves multiple molecular pathways, making it a challenge for clinicians to identify effective therapies. Pulmonary artery smooth muscle cells (PASMCs) play a crucial role in HPH pathogenesis by proliferating, resisting apoptosis, and promoting vascular remodelling. Curcumin, a natural polyphenolic compound, has shown potential as a therapeutic agent for HPH by reducing pulmonary vascular resistance, inhibiting vascular remodelling, and promoting apoptosis of PASMCs. Regulation of PASMCs could significantly inhibits HPH. However, curcumin has the disadvantages of poor solubility and low bioavailability, and its derivative WZ35 has better biosafety. Here, Cu-based metal organic frameworks (MOF

Indexed as

CurcuminMetal-Organic FrameworksAnimalsCell ProliferationCells, CulturedDiarylheptanoidsMyocytes, Smooth MusclePulmonary ArteryRatsRats, Sprague-DawleyVascular RemodelingCurcuminDiarylheptanoidsMetal-Organic FrameworksWZ35 compounddrug delivery systemsnanobiotechnologynanoparticlespulmonary hypertension

Identifiers

PMID37194386
PMCPMC10374547
OpenAlexW4376872672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.